The Neurotech Leaders Forum 2025, held at the Embassy Suites San Francisco Airport Oyster Point on November 5-6, 2025, convened top minds from the neuromodulation and neurotechnology sectors, including academic leaders, industry experts, investors, and entrepreneur innovators. The conference celebrated 25 years of editorial coverage from Neurotech Reports and showcased a dynamic agenda of keynote addresses, expert panels, and strategic networking opportunities, positioning itself as a must-attend event for professionals navigating the future of neurotechnology.

Day one addressed the state of the neurotechnology industry, highlighting recent market shifts such as notable mergers and acquisitions—Boston Scientific’s purchase of Nalu and Globus’ merger with Nevro—and the increasing involvement of private investors to offset funding gaps. Panels explored the hurdles of traversing the “Valley of Death” in business sustainability, the emergence of new implanting clinicians reshaping therapy delivery, and discussed strategies for building robust companies in a rapidly consolidating sector.

Entrepreneur panels provided valuable insights into cutting-edge startups and research organizations making an impact in neuromodulation, with presentations from Nuri Braintech, Aurimod GmbH, and OhmBody, among others. The AI-Driven BCI Revolution panel demonstrated the accelerating role of artificial intelligence in brain-computer interface development, forecasting transformative effects for speech restoration, psychiatric applications, and noninvasive technology markets.

Regulatory and reimbursement evolutions were dissected by industry veterans. Kristen Mittal of Mittal Consulting provided key insights including perspectives on outcome-driven reimbursement models as a safeguard against commoditization and restricted access, especially in the spinal cord stimulation (SCS) domain. Leaders advocated for a shift from procedure-based valuation to real-world, durable outcomes, echoing growing sentiment in both U.S. and international markets for cost-effectiveness and genuine patient value.

Day two broadened its scope to encompass pain neuromodulation advances, wearable technology, and the expansion of neuromodulation therapies beyond the central nervous system. Discussions featured from Biotronik Neuro, Medtronic, and Presidio Medical explored innovative therapies for conditions such as diabetic pain, migraine, and fibromyalgia, while wearables and consumer applications emerged as major frontiers, with Kernel and Cognito Therapeutics presenting breakthroughs.

Key takeaways include the critical momentum of private investment, the push for meaningful reimbursement alignment, consolidation trends, and the vital importance of innovation as illustrated by product launches and strategic alliances. For potential clients, the Neurotech Leaders Forum offers a snapshot of a sector embracing disruption yet committed to collaborative growth, rigorous clinical value, and adaptive business models positioned for the next era of neurotechnology.